Trimethylamine-N-oxide (TMAO) predicts fatal outcomes in community-acquired pneumonia patients without evident coronary artery disease

Published: 24 August 2016
Author(s): Manuel Ottiger, Manuela Nickler, Christian Steuer, Jonas Odermatt, Andreas Huber, Mirjam Christ-Crain, Christoph Henzen, Claus Hoess, Robert Thomann, Werner Zimmerli, Beat Mueller, Philipp Schuetz
Issue: August 2016
Section: Original Article

The pro-atherosclerotic metabolite trimethylamine-N-oxide (TMAO) is a risk factor for incident cardiovascular events and a potentially modifiable mediator of chronic inflammation through broad-spectrum antibiotic treatment by changing the microbiome. Whether TMAO is associated with adverse clinical outcomes in acute inflammatory community-acquired pneumonia (CAP) patients is unknown.